Journal article
High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer
A Willems-Jones, L Kavanagh, D Clouston, D Bolton, S Fox, H Thorne
BJU International | WILEY | Published : 2012
Abstract
OBJECTIVES • To determine if high grade prostatic intraepithelial neoplasia (HGPIN), which is considered a precursor to the development of prostate adenocarcinoma, displays the same genetic hallmarks as adenocarcinoma. • To identify, using molecular genetic techniques, if HGPIN is a precursor of tumour development and progression in men carrying a pathogenic germline mutation in BRCA2 . PATIENTS AND METHODS • Ten participants from the Kathleen Cuningham Consortium for Research into Familial Breast Cancer cohort of high-risk breast cancer families were identified, with (i) a diagnosis of aggressive prostate cancer and presence of HGPIN, (ii) a pathogenic BRCA2 mutation, and (iii) access to ar..
View full abstractRelated Projects (2)
Grants
Awarded by NHMRC
Funding Acknowledgements
We would like to thank Associate Professor Ian Campbell, Dr Ella Thompson and Professor Joe Sambrook for their invaluable assistance, advice and guidance throughout the development of this project and preparation of the manuscript. We would also like to thank Dr Sarah Ellis (Head of Microscopy Core, Peter MacCallum Cancer Centre) for her expert assistance and instruction on laser capture microdissection. We also wish to thank the kConFab data manager, Eveline Niedermayr; the kConFab research nurses and staff; the heads and staff of the Family Cancer Clinics; and the Clinical Follow-Up Study (funded by NHMRC grants 145684, 288704 and 454508) for their contributions to this resource. Special thanks go to the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia.